Uniprot/Swiss-prot ID |
INSR_HUMAN |
Protein name |
Insulin receptor |
Gene name |
Name: INSR |
Organism |
Homo sapiens (Human). |
Taxonomic lineage |
Eukaryota > Metazoa > Chordata > Craniata > Vertebrata > Euteleostomi > Mammalia > Eutheria > Euarchontoglires > Primates > Haplorrhini > Catarrhini > Hominidae > Homo. |
Function |
Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. |
PTM |
N-linked (Glc...)N-linked (GlcNAc...)PhosphoserinePhosphotyrosineDePhosphotyrosineS-nitrosocysteine |
Topology Preview |
|
Localization |
Cell membrane; Single-pass type I membrane protein. |
Gene Ontology(GO) |
C:caveolaC:endosome membraneC:insulin receptor complexF:ATP bindingF:GTP bindingF:insulin bindingF:insulin-activated receptor activityF:insulin-like growth factor receptor bindingF:receptor signaling protein tyrosine kinase activityP:activation of MAPK activityP:activation of protein kinase B activityP:carbohydrate metabolic processP:cellular response to growth factor stimulusP:exocrine pancreas developmentP:G-protein coupled receptor signaling pathwayP:glucose homeostasisP:heart morphogenesisP:male sex determinationP:peptidyl-tyrosine phosphorylationP:positive regulation of cell migrationP:positive regulation of cell proliferationP:positive regulation of developmental growthP:positive regulation of DNA replicationP:positive regulation of glucose importP:positive regulation of glycogen biosynthetic processP:positive regulation of glycolysisP:positive regulation of mitosisP:positive regulation of nitric oxide biosynthetic processP:positive regulation of protein kinase B signaling cascadeP:positive regulation of respiratory burstP:protein autophosphorylationP:protein heterotetramerizationP:regulation of embryonic developmentP:regulation of transcription, DNA-dependentP:transformation of host cell by virus |
InterPro |
IPR000494: EGF_rcpt_LIPR003961: Fibronectin_type3IPR006211: Furin-like_Cys-rich_domIPR006212: Furin_repeatIPR009030: Growth_fac_rcpt_N_domIPR013783: Ig-like_foldIPR011009: Kinase-like_domIPR000719: Prot_kinase_cat_domIPR017441: Protein_kinase_ATP_BSIPR001245: Ser-Thr/Tyr_kinase_cat_domIPR008266: Tyr_kinase_ASIPR020635: Tyr_kinase_cat_domIPR016246: Tyr_kinase_insulin-like_rcptIPR002011: Tyr_kinase_rcpt_2_CS |
PDB |
Entry | Method | Å | Chain | Positions | 3D | 1GAG | X-ray | 2.70 | A | 1005-1310 |  | 1I44 | X-ray | 2.40 | A | 1005-1310 |  | 1IR3 | X-ray | 1.90 | A | 1005-1310 |  | 1IRK | X-ray | 2.10 | A | 1005-1310 |  | 1P14 | X-ray | 1.90 | A | 1005-1298 |  | 1RQQ | X-ray | 2.60 | A/B | 1005-1310 |  | 2AUH | X-ray | 3.20 | A | 1005-1310 |  | 2B4S | X-ray | 2.30 | B/D | 1005-1310 |  | 2DTG | X-ray | 3.80 | E | 28-943 |  | 2HR7 | X-ray | 2.32 | A/B | 28-512 |  | 2Z8C | X-ray | 3.25 | A | 1009-1310 |  | 3BU3 | X-ray | 1.65 | A | 1005-1310 |  | 3BU5 | X-ray | 2.10 | A | 1005-1310 |  | 3BU6 | X-ray | 1.95 | A | 1005-1310 |  | 3EKK | X-ray | 2.10 | A | 1005-1310 |  | 3EKN | X-ray | 2.20 | A | 1005-1310 |  | 3ETA | X-ray | 2.60 | A/B | 1017-1322 |  | 3LOH | X-ray | 3.80 | E | 28-956 |  | 3W11 | X-ray | 3.90 | E | 28-337, F |  | 3W12 | X-ray | 4.30 | E | 28-337, F |  | 3W13 | X-ray | 4.30 | E | 28-337, F |  | 3W14 | X-ray | 4.40 | E | 28-620, F |  | |
Sequence |
Length: 1382 |
MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS
|
|
Kegg Pathway |
hsa04066:HIF-1 signaling pathway - Homo sapiens (human)hsa04151:PI3K-Akt signaling pathway - Homo sapiens (human)hsa04520:Adherens junction - Homo sapiens (human)hsa04910:Insulin signaling pathway - Homo sapiens (human)hsa04913:Ovarian steroidogenesis - Homo sapiens (human)hsa04930:Type II diabetes mellitus - Homo sapiens (human)hsa04960:Aldosterone-regulated sodium reabsorption - Homo sapiens (human) |
Disease Reference |
KEGG disease |
H00719: Leprechaunism; Donohue syndromeH00942: Rabson-Mendenhall syndromeH01228: Insulin-resistant diabetes mellitus with acanthosis nigricans (IRAN); Type A insulin resistanceH01267: Familial hyperinsulinemic hypoglycemia (HHF) |
Omim |
147670: INSULIN RECEPTOR; INSR246200: DONOHUE SYNDROME ;;LEPRECHAUNISM INSULIN RECEPTOR, DEFECT IN, INCLUDED262190: PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATIC ABNORMALITIES ;;MENDENH609968: HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5; HHF5610549: DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS ;;INSULIN RECEPTOR, DEFECT I |
|
Drug Reference |
Kegg drug |
D00085: Insulin (JAN/USP)D03230: Insulin human (genetical recombination) (JP16); Insulin human (biosynthesis) (JAN); Insulin human (sD03250: Insulin glargine (genetical recombination) (JAN); Insulin glargine (USAN/INN); Lantus (TN)D04475: Insulin aspart (genetical recombination) (JAN); Insulin aspart (USAN/INN); Insulin X 14; NovoRapid (D04477: Insulin lispro (genetical recombination) (JAN); Insulin lispro (USP/INN); Humalog (TN)D04539: Insulin detemir (genetical recombination) (JAN); Insulin detemir (USAN/INN); Levemir (TN)D04540: Insulin glulisine (genetical recombination) (JAN); Insulin glulisine (USAN/INN); Apidra (TN)D04541: Insulin human, isophane (USP)D04542: Insulin human zinc (USP)D04543: Insulin human zinc, extended (USP)D04544: Insulin I 125 (USAN); Imusay-125 (TN)D04545: Insulin I 131 (USAN); Imusay-131 (TN)D04546: Insulin, dalanated (USAN)D04547: Isophane insulin injection (aqueous suspension) (JAN); Insulin, isophane (USP); Humalog PEN (TN)D04548: Insulin, neutral (USAN); Neutral insulin injection (INN)D04549: Insulin zinc, extended (USP); Ultralente iletin (TN)D04550: Insulin zinc, prompt (USP); Semilente iletin (TN)D04551: Insulin zinc (USP); Lente iletin (TN)D05622: Proinsulin human (USAN)D08080: Insulin injection, biphasic isophane (BAN); Insulin Humacart (TN)D09727: Insulin degludec (genetical recombination) (JAN); Insulin degludec (USAN/INN); Tresiba (TN) |
DrugBank |
DB00047: Insulin Glargine recombinantDB00030: Insulin recombinantDB00071: Insulin, porcine |
|